Alumis (ALMS) Treasury Shares (2023 - 2024)
Alumis' (ALMS) quarterly Treasury Shares came in at $168.5 million in Q2 2024, up 96.01% quarter-over-quarter from $86.0 million in Q4 2023.
Powered by 
Analysis
Alumis (ALMS) Treasury Shares (2023 - 2024) Analysis & Trends
Alumis (ALMS) has reported Treasury Shares for 2 consecutive years, with $168.5 million the latest figure, recorded in Q2 2024.
- On a quarterly basis, Treasury Shares changed N/A year-over-year to $168.5 million in Q2 2024; TTM through Jun 2024 was $168.5 million, a N/A change from a year earlier, with the FY2023 full-year figure at $86.0 million, changed N/A from the prior year.
- Treasury Shares was $168.5 million for Q2 2024 at Alumis, up from $86.0 million in the prior quarter.
- Over five years, Treasury Shares peaked at $168.5 million in Q2 2024 and troughed at $86.0 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 36.40 Mn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -23.80 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Alumis | 966.94 Mn | 464.65 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 168.49 Mn |
| Jun 30, 2024 | 168.49 Mn |
| Dec 31, 2023 | 85.96 Mn |
| Dec 31, 2023 | 85.96 Mn |